{"nctId":"NCT00456521","briefTitle":"A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program","startDateStruct":{"date":"2007-03"},"conditions":["Obesity","Overweight"],"count":793,"armGroups":[{"label":"NB32","type":"EXPERIMENTAL","interventionNames":["Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day","Behavioral: Intensive group lifestyle modification counseling"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Behavioral: Intensive group lifestyle modification counseling"]}],"interventions":[{"name":"Naltrexone SR 32 mg/ bupropion SR 360 mg/ day","otherNames":["NB32"]},{"name":"Placebo","otherNames":[]},{"name":"Intensive group lifestyle modification counseling","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male subjects aged 18 to 65 years (inclusive)\n* Body mass index (weight \\[kg\\]/height \\[m²\\]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with controlled hypertension and/or dyslipidemia\n* Non-smoker and had not used tobacco or nicotine products for at least 6 months before screening\n* Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers, beta-blockers, and clonidine. Medical regimen was to be stable for at least 8 weeks.\n* Low-density lipoprotein level \\<190 mg/dL and triglycerides level \\<400 mg/dL. Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 8 weeks.\n* No clinically significant abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, bilirubin, calcium and phosphorus\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 times upper limit of normal (ULN)\n* No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or platelets\n* Fasting glucose ≤126 mg/dL and not receiving hypoglycemic agents\n* No clinically significant abnormality on urinalysis\n* Thyroid stimulating hormone (TSH) within 1.5 times ULN or normal triiodothyronine (T3), if TSH was below normal limits\n* Female subjects of childbearing potential had a negative serum pregnancy test\n* An IDS-SR score \\<2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \\<30\n* Female subjects of childbearing potential were non-lactating and agreed to continue to use effective contraception throughout the study and 30 days after discontinuation of study drug\n* Completed a food diary for 6 of 7 consecutive days during screening\n* Able to comply with all required study procedures and schedule\n* Able to speak and read English\n* Provided written informed consent\n\nExclusion Criteria:\n\n* Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)\n* Serious medical condition (including but not limited to renal or hepatic insufficiency; congestive heart failure, angina pectoris, myocardial infarction, stroke, claudication, or acute limb ischemia; history of malignancy with exception of non-melanoma skin cancer or surgically cured cervical cancer)\n* Serious psychiatric illness (e.g., lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, e.g., borderline; severe major depressive disorder, recent \\[previous 6 months\\] suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness)\n* Response to the bipolar disorder questions that indicated the presence of bipolar disorder.\n* Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months\n* History of drug or alcohol abuse or dependence within 1 year\n* Type I or Type II diabetes mellitus\n* Baseline ECG with a corrected QT (QTc) interval (using Bazett's formula \\>450 millisecond (msec) \\[males\\] and \\>470 msec \\[females\\]) or the presence of any clinically significant cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities\n* Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia; any anorectic or weight loss agents; any over-the-counter dietary supplements with psychoactive, appetite or weight effects; alpha-adrenergic blockers; beta-blockers; clonidine; coumadin; theophylline; cimetidine; oral corticosteroids; topiramate, Depo-Provera®; smoking cessation agents; regular use of opioid or opioid-like analgesics\n* History of surgical or device (e.g., lap band) intervention for obesity\n* History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with \\>5 minutes loss of consciousness, concussion symptoms lasting \\>15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)\n* History of treatment with bupropion or naltrexone within the preceding 12 months\n* History of hypersensitivity or intolerance to bupropion or naltrexone\n* Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to baseline\n* Loss or gained \\>4.0 kilograms within the previous 3 months\n* Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug\n* Planned surgical procedure that could impact the conduct of the study\n* Received any investigational drug or used an experimental device or procedure within the previous 30 days\n* Participated in any previous clinical trial conducted by Orexigen\n* Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Co-primary: Body Weight- Mean Percent Change","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.29","spread":"0.40"},{"groupId":"OG001","value":"-5.08","spread":"0.60"}]}]}]},{"type":"PRIMARY","title":"Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.39","spread":null},{"groupId":"OG001","value":"42.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Body Weight- Proportion of Subjects With ≥10% Decrease","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.49","spread":null},{"groupId":"OG001","value":"20.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.98","spread":"0.48"},{"groupId":"OG001","value":"-6.77","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Triglycerides Levels, Using Log-transformed Data","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.62","spread":null},{"groupId":"OG001","value":"-8.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Insulin Levels, Using Log-transformed Data","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.98","spread":null},{"groupId":"OG001","value":"-15.45","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting HDL Cholesterol Levels","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":"0.51"},{"groupId":"OG001","value":"0.87","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Change in IWQOL-Lite Total Scores","description":"IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.43","spread":"0.56"},{"groupId":"OG001","value":"10.29","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Change in HOMA-IR Levels, Using Log-transformed Data","description":"HOMA-IR= Homeostasis Model Assessment-Insulin Resistance","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.93","spread":null},{"groupId":"OG001","value":"-16.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.87","spread":null},{"groupId":"OG001","value":"-16.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Glucose Levels","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.36","spread":"0.62"},{"groupId":"OG001","value":"-1.08","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting LDL Cholesterol","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","spread":"1.36"},{"groupId":"OG001","value":"8.13","spread":"2.13"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.32","spread":"0.47"},{"groupId":"OG001","value":"-3.87","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure","description":null,"paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.41","spread":"0.33"},{"groupId":"OG001","value":"-2.78","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Change in IDS-SR Total Scores","description":"IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.23"},{"groupId":"OG001","value":"-0.00","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Sweets Subscale Scores","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.54","spread":"0.22"},{"groupId":"OG001","value":"-2.43","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Change in Food Craving Inventory Carbohydrates Subscale Scores","description":"The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.06","spread":"0.20"},{"groupId":"OG001","value":"-1.97","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire","description":"Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.75","spread":"1.17"},{"groupId":"OG001","value":"-8.46","spread":"1.75"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":584},"commonTop":["Nausea","Headache","Constipation","Dizziness","Vomiting"]}}}